Week of September 7th 2021 | Vol. 10, Issue 36
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business

Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Contract drug manufacturer Catalent Inc. CTLT -0.66% said Monday that it has agreed to buy closely held Bettera Holdings LLC for $1 billion, the latest deal involving nutritional supplement companies.

The all-cash deal expands Catalent’s manufacturing capabilities for vitamins, minerals and supplements to make them in gummy form. The transaction is expected to close by the end of the fourth quarter.

The deal was first reported by The Wall Street Journal on Sunday.

Bettera, based in Plano, Texas, and backed by private-equity firm Highlander Partners LP, manufactures gummy, soft-chew and lozenge forms of vitamins and supplements. Bettera has about 500 employees.
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
11 transactions totaling $9,480 million
Supplies, Equipment & Services
13 transactions totaling $12,248 million
Healthcare IT & Managed Care
3 transactions totaling $93 million
Healthcare Facilities & Distributors
14 transactions totaling $95 million
Pharma & Biotech
23 transactions totaling $609 million
Supplies, Equipment & Services
21 transactions totaling $569 million
Healthcare IT & Managed Care
15 transactions totaling $239 million
Healthcare Facilities & Distributors
2 transactions totaling $100 million
Pharma & Biotech
3 transactions totaling $500 million
Supplies, Equipment & Services
6 transactions totaling $592 million
Healthcare IT & Managed Care
1 transaction totaling $44 million
Healthcare Facilities & Distributors
3 transactions totaling $461 million
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
August 30, 2021 - Fierce Biotech
Laronde launched out of Flagship Labs this year with a lofty vision: to deliver as many as 100 new RNA medicines over the next 10 years. Now, it’s fueling that goal with a major $440 million round. “The amount of money raised reflects our ambitions. We wanted to build a big company—and we need big money to build a big company,” said Diego Miralles, M.D., CEO of Laronde and a CEO-partner at Flagship Pioneering. The company spent years under the radar at Flagship’s incubator and uncloaked in May with $50 million. 

August 30, 2021 - Fierce Biotech
With regular venture funding rounds and a handful of new strategic partnerships and technology launches in recent years, expanding the reach of its telegenomics service platform has become a core piece of Genome Medical’s DNA. Now, Genome Medical is taking a two-pronged approach: Alongside raking in $60 million in new financing, it also made a bid for GeneMatters, a Minneapolis-based provider of virtual genetic counseling services. The series C funding round was led by Casdin Capital. More than a dozen other new and existing investors also joined in, including Alphabet’s GV, Amgen Ventures, Illumina Ventures, Kaiser Permanente Ventures and more.

September 2, 2021 - Fierce Healthcare
Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, payers and other industry players look to expand their businesses and gain a competitive edge. Here’s a roundup of new deals that were revealed, closed or called off during the month of August.

September 2, 2021 - Fierce Biotech
After months of rumors and reports, Baxter has finally landed on a price to acquire fellow medtech company Hill-Rom—and it's nearly a billion dollars above where talks started earlier this summer. Weighing in at about $10.5 billion in equity value—or about $12.4 billion all told, when including Baxter’s assumption of Hill-Rom’s debts and cash on hand—the deal amount has swelled since news in late July that Hill-Rom had rebuffed an offer totaling about $9.6 billion.
Events Hosted or Attended by Bourne Partners

November 9-11, 2021 - Milan, Italy

January 10-14, 2022 - San Francisco, CA
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.